Fig. 2: Glucose sensitivity. | Nature Communications

Fig. 2: Glucose sensitivity.

From: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

Fig. 2: Glucose sensitivity.

a The insulinogenic index (ΔC30/ΔG30) (sitagliptin, n = 11; sitagliptin + dorzagliatin, n = 15; dorzagliatin, n = 14), b total GLP-1 secretion index (ΔGLP-1total.30/ΔG30) (sitagliptin, n = 11; sitagliptin + dorzagliatin, n = 15; dorzagliatin, n = 14), and c active GLP-1 secretion index (ΔGLP-1active.30/ΔG30) (sitagliptin, n = 8; sitagliptin + dorzagliatin, n = 9; dorzagliatin, n = 10) are calculated based on the C-peptide and GLP-1 levels in the OGTT study. A diagonal bar and empty circles represent the mean and individual index under sitagliptin monotherapy, gray bar, and empty squares represent the mean and individual index under sitagliptin + dorzagliatin therapy, white bar and empty triangles represent the mean and individual index under dorzagliatin monotherapy. Error bars represent standard deviation. The p value was calculated based on the paired Wilcoxon test between combination therapy and each monotherapy. *p < 0.05, **p < 0.01 compared with combination treatment. OGTT oral glucose tolerance test.

Back to article page